Iovance Biotherapeutics (IOVA) Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall St slips as Middle East uncertainty lifts oil; Trump-Xi talks in focus
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Plug Power COO resigns to join another company
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Wall Street ends down as oil prices, Treasury yields rise
Iovance Biotherapeutics, Inc. Announces Proposed Public Offering of Common Stock
July 10, 2023 4:34 PM EDTSAN CARLOS, Calif., July 10, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (Iovance or Company), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that it intends to offer and sell $150 million of shares of its common stock, subject to market and other conditions, in an underwritten public offering. All of the shares in the offering are to be sold by Iovance. Iovance intends to grant the underwriters a 30-day option to purchase an additional $22.5 million of shares of common stock... More
